A previous study found that PD-L2 expression in tumor cells significantly suppressed anti-tumor immune responses by exhausting CD8+ T cells in renal cell carcinoma (RCC) and lung squamous cell carcinoma (LUSC), which contributes to development of resistance to anti-PD-L1 treatment. This evidence concerns the gene CD8A and neoplasm.